NASDAQ:VOR

Vor Biopharma Stock News

Healthcare > Biotechnology

Buy VOR

*Your capital is at risk

$21.15

-0.650 (-2.98%)

At Close: Jul 31, 2026

Vor Biopharma: It's A Game Of Wait And See

03:38pm, Wednesday, 08'th Apr 2026

Vor Biopharma Inc. has pivoted to immunology, raising over $500m in 2025 to advance telitacicept for U.S. approval. VOR holds $530m cash, extending its runway into 2029, but faces significant dilution

First Look: Pershing's UMG bid, Fed hawkish signals, GLP‑1 pill momentum

07:37am, Tuesday, 07'th Apr 2026

Stock News Markets edge higher before Iran deadline: Global equities were mixed and oil volatile ahead of President Trump's deadline on Iran's Hormuz reopening,

Vor Biopharma Inc. (NASDAQ:VOR) Given Consensus Recommendation of “Moderate Buy” by Analysts

02:58am, Monday, 06'th Apr 2026

Shares of Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) have earned a consensus rating of "Moderate Buy" from the thirteen ratings firms that are covering the stock, Marketbeat reports. One equit

Vor Biopharma (VOR) Upgraded to Buy: Here's Why

01:01pm, Thursday, 02'nd Apr 2026

Vor Biopharma (VOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know

10:56am, Thursday, 02'nd Apr 2026

The average of price targets set by Wall Street analysts indicates a potential upside of 107.8% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

05:00pm, Wednesday, 01'st Apr 2026

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on April 1, 2026, the

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

08:01am, Monday, 30'th Mar 2026

First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren's disease

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease

08:00am, Monday, 30'th Mar 2026

First and only dual BAFF/APRIL inhibitor in primary Sjögren's disease, one of the largest autoimmune diseases without an approved therapy First and only dual BAFF/APRIL inhibitor in primary Sjögren'

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by

Vor Biopharma Stock News

Vor Biopharma: It's A Game Of Wait And See

First Look: Pershing's UMG bid, Fed hawkish signals, GLP‑1 pill momentum

Vor Biopharma Inc. (NASDAQ:VOR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Vor Biopharma (VOR) Upgraded to Buy: Here's Why

Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease

What's Behind The Jump In Vor Biopharma Stock?

Vor Bio Announces $75 Million Private Placement with TCGX

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vor Biopharma Inc. (VOR) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference

Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of “Moderate Buy” from Brokerages

Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Top Fintech Company